GPE – Page 6 – Talk Bio

Actionable Insights Powered by AI

Taiho’s Investigational DMD Therapy Misses Primary Endpoint in Phase 3 Trial

2 months ago talkbio0Tagged Clinical trial failure, Muscular Dystrophy, Duchenne, Otsuka Holdings, pizuglanstat, REACH-DMD study, Taiho, TAS-205

Taiho; Duchenne muscular dystrophy; DMD; pizuglanstat; TAS-205; Phase 3 trial; clinical trial failure; REACH-DMD study; Otsuka Holdings

China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs

3 months ago talkbio0Tagged China approval, eli lilly, GCG, GCG/GLP-1 agonist, Glucagon-Like Peptide 1, Innovent Biologics, mazdutide, N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide, Obesity, Weight maintenance regimen

Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management

Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

3 months ago talkbio0Tagged alliance, Autistic Disorder, Centers for Disease Control and Prevention (U.S.), Confirmation, Gavi Vaccine, Monarez, Nominee, Robert F. Kennedy Jr., Senate, Susan, Trump administration, Vaccine Safety, Vaccines

Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance

Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move

3 months ago talkbio0Tagged Bayer, bemdaneprocel, BlueRock Therapeutics, Cambridge research labs, Cell Therapy, Drug Industry, layoffs

BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

3 months ago talkbio0Tagged BioNTech, BNT211, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Clinical Trials, Gaithersburg, layoffs, Manufacturing Facilities, Maryland (geographic location)

BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial

Gilead Lays Off 36 Employees After Cancelling Oceanside, California Expansion

3 months ago talkbio0Tagged Biological Factors, biotech industry, California, co-location, expansion, Facility (object), Foster City, Gilead Sciences, layoffs, Oceanside

Gilead Sciences; layoffs; Oceanside; California; biologics; facility expansion; job cuts; biotech industry; co-location; Foster City

UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity

3 months ago talkbio0Tagged Biological Factors, biomanufacturing, economic impact, expansion, Investments, Manufacturing, U.S., UCB

UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

3 months ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs

Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Bay Area, biotech industry, Dosage Forms, genentech, layoffs, Roche (company), South San Francisco, WARN filing

Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry

Ex-HHS Workers Accuse Trump Administration of Using Flawed Data to Justify Mass Firings

3 months ago talkbio0Tagged Agencies, CHARGE Syndrome, disability services, firings, Medicare, Project, public servants, Trump administration

HHS firings; Trump administration; federal workforce; flawed data; Project 2025; agency cuts; disability services; Medicare; public servants